Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 11/20 | 0.44 |
| ▸ | MAOB | P27338 | 11/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19182080 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19182281 | 0.82 | PTPN1 (0.59) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL28318700 | 0.77 | ALDH1A1 (0.70) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19182263 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19196841 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19182262 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19180463 | 0.74 | MAPT (0.67) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19180460 | 0.74 | MAPT (0.67) | ALDH1A1MAPTLMNAMAOAMAOB | |
| SCHEMBL19182131 | 0.70 | ALDH1A1 (0.42) | ALDH1A1PTPN1 | |
| SCHEMBL20917027 | 0.65 | ALDH1A1 (0.37) | ALDH1A1MAPTLMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3407974-A1 | AMLEXANOX ANALOGS | The Regents Of The University Of Michigan (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20170217980-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-08-03 | — | — | US | disclosed |
| WO-2017132538-A1 | AMLEXANOX ANALOGS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217980-A1 | AMLEXANOX ANALOGS | GPR119, GLP1R, IRS1 | ALDH1A1 1946/4885MAPT 4441/4885LMNA 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.